Compare Crocs, Inc. (CROX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Crocs, Inc. trades at $131.17 (market cap $6.52B), while Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.78B). The key difference: Crocs, Inc. is far larger — about 3.7× Recursion Pharmaceuticals Inc's market cap, and Crocs, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CROX | RXRX | |
|---|---|---|
Market Cap | $6.52B | $1.78B |
Sector | Consumer Staples | Health |
52-Week High | $132.78 | $6.79 |
52-Week Low | $73.39 | $2.84 |
Enterprise Value | $8.11B | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $130.46, down 1.75% on the day, with strong technical momentum indicated by bullish moving averages and a potential breakout pattern forming. The company has consistently beaten earnings estimates in recent quarters, though 2025 showed a net loss of $81.20M. Strategic partnerships with LEGO and Disney are driving brand innovation, while international growth, particularly in Asia, provides expansion opportunities.
The stock presents a mixed outlook with bullish analyst sentiment (51% buy ratings) and a $131.29 consensus price target offering modest upside. Key risks include recent profitability challenges, high debt levels, and competitive pressures in the footwear sector. Revenue stability and brand strength support long-term potential, but margin recovery remains critical for sustained growth.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
